- Trade options, futures, options on futures, stocks, ETFs
- $0 commission to close options
- Pro-grade platform and risk analysis tools
Finder makes money from featured partners, but editorial opinions are our own.
Advertiser disclosure
GT Biopharma, a company that develops novel immuno-oncology biopharmaceutical drugs, is looking to be listed on the Nasdaq. The company is currently listed on the Over-the-Counter Markets under the ticker symbol "GTBP." It hopes to trade on the Nasdaq under the same ticker symbol.
What's in this guide?
Our top picks for where to buy GT Biopharma stock
- Trade $0 commission stocks & ETFs with as little as $1
- Earn up to $300 with qualifying deposits
- Discover new opportunities with Opto's AI-driven thematic investing system
- Theme and ETF screener
- Trade stocks, options, ETFs, mutual funds, alternative asset funds
- $0 commission on stocks, ETFs and options with no options contract fees
- Get up to $1,000 in stock when you fund a new account within 30 days
- Complimentary access to a financial planner
Probability of member receiving $1,000 is 0.028%
How to buy Gt Biopharma Inc stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – GTBP. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Gt Biopharma Inc stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.1 - 4 of 4
What is the Finder Score?
The Finder Score crunches 147 key metrics we collected directly from 18+ brokers and assessed each provider’s performance based on nine different categories, weighing each metric based on the expertise and insights of Finder’s investment experts. We then scored and ranked each provider to determine the best brokerage accounts.
We update our best picks as products change, disappear or emerge in the market. We also regularly review and revise our selections to ensure our best provider lists reflect the most competitive available.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
Gt Biopharma Inc stock price (NASDAQ: GTBP)
Use our graph to track the performance of GTBP stocks over time.Gt Biopharma Inc shares at a glance
Information last updated 2024-12-15.
| Latest market close | $3.20 |
|---|---|
| 52-week range | $1.86 - $10.66 |
| 50-day moving average | $2.63 |
| 200-day moving average | $3.13 |
| Wall St. target price | $11.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-7.39 |
Is it a good time to buy Gt Biopharma Inc stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gt Biopharma Inc price performance over time
Historical closes compared with the close of $1.745 from 2024-12-20
| 1 week (2024-12-17) | -29.92% |
|---|---|
| 1 month (2024-11-25) | -41.05% |
| 3 months (2024-09-24) | -12.75% |
| 6 months (2024-06-24) | -40.65% |
| 1 year (2023-12-22) | 570.64% |
|---|---|
| 2 years (2022-12-23) | -94.66% |
| 3 years (2021-12-23) | 111.6 |
| 5 years (2019-12-24) | 41.82 |
Gt Biopharma Inc financials
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -60.59% |
| Return on equity TTM | -131.48% |
| Profit margin | 0% |
| Book value | $5.41 |
| Market Capitalization | $6.2 million |
TTM: trailing 12 months
Gt Biopharma Inc share dividends
We're not expecting Gt Biopharma Inc to pay a dividend over the next 12 months.
You may also wish to consider:
Have Gt Biopharma Inc's shares ever split?
Gt Biopharma Inc's shares were split on a 1:30 basis on 4 February 2024 . So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Gt Biopharma Inc shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Gt Biopharma Inc shares which in turn could have impacted Gt Biopharma Inc's share price.
Gt Biopharma Inc share price volatility
Over the last 12 months, Gt Biopharma Inc's shares have ranged in value from as little as $1.86 up to $10.6599. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gt Biopharma Inc's is 0.57. This would suggest that Gt Biopharma Inc's shares are less volatile than average (for this exchange).
To put Gt Biopharma Inc's beta into context you can compare it against those of similar companies.
- Chinook Therapeutics (KDNY.US): 0.6734
- GeoVax Labs (GOVX.US): 3.109
Gt Biopharma Inc overview
GT Biopharma, Inc. , a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc.
Frequently asked questions
nullWhat percentage of Gt Biopharma Inc is owned by insiders or institutions?
Currently 12.148% of Gt Biopharma Inc shares are held by insiders and 67.517% by institutions. How many people work for Gt Biopharma Inc?
Latest data suggests 2 work at Gt Biopharma Inc. When does the fiscal year end for Gt Biopharma Inc?
Gt Biopharma Inc's fiscal year ends in December. Where is Gt Biopharma Inc based?
Gt Biopharma Inc's address is: 8000 Marina Boulevard, Brisbane, CA, United States, 94005 What is Gt Biopharma Inc's ISIN number?
Gt Biopharma Inc's international securities identification number is: US36254L2097
More resources on Finder
More guides on Finder
-
Best Stocks for Beginners With Little Money to Invest
These are the stocks to buy when you don’t have much to spend.
-
Sweep Accounts
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
-
7 Best Day Trading Apps of 2024
These are the best day trading apps, according to Finder’s comprehensive analysis.
-
Today’s Best Brokerage Account Bonuses [Signup and Transfer Promos]
Explore the best bonuses for opening a new brokerage account.
-
5 best stock picking services of 2024
Compare the 5 best stock picking services, according to Finder’s analysis, and learn how to choose the best option for your needs.
-
5 Top Graphene Stocks to Invest in Today
We’ve rounded up stats on some of the most popular graphene stocks, along with information on how they compare and how to invest.
-
Ratings methodology for online brokers
Our star ratings for online brokerages are based on how they stack up in nine key categories.
-
How to invest in the S&P 500 in 2024
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to Invest $10K
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
-
5 best ETFs for 2024
Check out the best-performing ETFs so far in 2024.
Ask a question